ACE Genotype

Reading the DNA of the ACE gene does two very different jobs. It can find rare inherited changes in both copies that cause severe kidney disease in newborns or later kidney disease in some families. It can also help explain why your blood level of the enzyme runs high or low, but only if the report includes the well-known insertion/deletion genotype. It should not be used as a heart attack prediction test. The largest heart studies on this gene do not support that use.

There is a catch before you order. The variant most people mean when they say ACE genotype is a 287-letter Alu insertion in a non-coding stretch of the gene. It is either present or absent, and many sequencing reports do not call it.

What Sequencing Reads, and What It Usually Skips

You carry two copies of ACE, one from each parent. They hold the instructions for angiotensin-converting enzyme, which is made by cells lining blood vessels and by several other tissues. Sequencing reads the parts of those instructions the assay covers and flags changes it is designed to detect: a swapped letter, a small missing piece, or a change likely to damage the finished protein.

The famous I/D variant is different. It is a repeated Alu element of DNA, about 287 letters long, present in some copies of the gene and absent in others. The present version is called I, for insertion. The absent version is called D, for deletion. That gives three possible results: II, ID, or DD.

That variant is traditionally measured by sizing a DNA fragment after a targeted lab reaction, not by reading each letter. Standard short-read sequencing and exome sequencing can miss longer insertions, repeat-rich regions, and non-coding variants unless the lab has built a specific call for them. If the I/D result is the reason you are ordering, check the sample report first.

Your Natural Baseline for the Enzyme

One finding has held up since 1990. The I/D variant, measured by targeted genotyping rather than routine sequencing, accounts for close to half of the person-to-person variation in how much of this enzyme circulates in your blood. People with two deletion copies carry roughly double the level of people with two insertion copies. Family studies put the gene's total contribution near 44 percent, so the I/D variant is not the whole story, but it is most of it.

That matters in one specific situation. Blood levels of this enzyme help evaluate and follow sarcoidosis. Sarcoidosis is an inflammatory disease that can form clumps of immune cells in the lungs and other organs. Lab reference ranges are built from mixed populations, so a DD person can look abnormally high while perfectly healthy, and an II person can have active disease at a level that still reads normal.

Genotype-adjusted reference values have been published for exactly this reason, and they improve both the ability to catch active disease and the ability to clear people who do not have it. If an enzyme level is being used to track your sarcoidosis, knowing which of the three genotypes you carry changes how that number should be read.

Rare Variants That Cause Kidney Failure in Newborns

When both copies of this gene are severely damaged, the kidneys may not develop normally. The condition is renal tubular dysgenesis. The urine-making tubules fail to form, the fetus makes too little urine, fluid around the fetus falls, and many affected newborns die before or soon after birth. Sequencing can give a molecular diagnosis here, and related genes in the same hormone pathway can cause the same pattern.

Milder versions exist. People with two damaged copies have turned up later in life with slowly progressive chronic kidney disease, anemia, and heavy thirst and urination, a picture that had gone unexplained until someone sequenced them.

This is the strongest reason to order the test. Broad inherited kidney disease panels are most useful when disease begins early, is severe, appears in several relatives, or occurs in a child whose parents are related. In those settings, sequencing can end a diagnostic search that ordinary kidney labs cannot.

Heart Attack Risk, and Why the Small Studies Disagreed

Early reports in the 1990s linked the DD genotype with heart attacks, enlarged weak heart muscle, and severe coronary narrowing. Those findings were real in the cohorts that produced them. Some smaller studies still find links in selected populations. Then the large studies arrived.

Sources: International Studies of Infarct Survival Collaborators; Lindpaintner et al., Physicians' Health Study; Rotterdam Study.

What this means for you: a DD result should not change your cardiac plan. The numbers that do predict heart attacks, and that you can act on, are ApoB, lipoprotein(a), blood pressure, and blood sugar. ApoB estimates the number of cholesterol-carrying particles in your blood.

Now hold two facts next to each other. The DD genotype produces more of an enzyme that constricts vessels and thickens tissue, and DD is also more common among centenarians than among younger controls, by roughly 40 percent in a pooled analysis. That stops being a contradiction once you quit treating this as a good gene or a bad gene. It is a common variant that nudges one enzyme level up or down, and a nudge in that direction can be mildly harmful in one organ, neutral in another, and trivial against the weight of blood pressure, smoking, diet, and everything else. Small studies catch the nudge and publish it. Large studies average it toward zero.

Kidney Outcomes in Diabetes

The most consistent common-variant finding in this gene is not about the heart. Among 1,155 people with long-standing type 1 diabetes, carrying at least one deletion allele roughly doubled the risk of major kidney events and was linked to a smaller rise in all-cause death over long follow-up. A pooled analysis in diabetic kidney disease also tied the D allele and DD genotype to end-stage kidney disease, with the clearest pooled signal in type 2 diabetes.

Similar signals appear elsewhere in kidney medicine. DD was found in 57 percent of people with biopsy-proven kidney damage from high blood pressure, against 25 percent of controls. It tracked with faster decline in IgA nephropathy, the most common inflammatory kidney disease worldwide. It was linked to higher death rates in people starting dialysis.

For most people, it does not change the core plan. With diabetes, the plan is the same either way: lower urine albumin, keep blood pressure down, check kidney function often. What a deletion-heavy result can reasonably do is push you to the aggressive end of that monitoring schedule instead of the relaxed end.

Reactions to Blood Pressure Medication

ACE inhibitors are common blood pressure and heart drugs. Two reactions have obvious biologic suspects: a dry persistent cough, and angioedema, sudden deep swelling of the lips, tongue, or airway. Sequencing has been used to hunt for the cause of both.

The results are humbling. In the largest effort, researchers sequenced 1,066 samples, including 408 people with angioedema on ACE inhibitors or angiotensin receptor blockers and 658 controls. The strongest signal was not in this gene at all. It was in F5, a blood clotting gene, where risk variants about doubled the odds. A five-person pilot found Factor V Leiden in all five people, a common synonymous ACE variant in two, and a rare ACE missense variant in one. Five people can generate leads. It cannot tell you which variant caused the swelling.

For the cough, one 107-person study in the United Arab Emirates linked it to the I/D genotype and to lower blood enzyme levels. For whether an ACE inhibitor will work for you, this genotype is not a reliable prescribing test. Measuring the enzyme directly has been argued for two decades to be more useful than reading the gene, but even that is not routine prescribing.

The Alzheimer's Question

This enzyme does more than manage blood pressure. It also clips amyloid-beta, the protein fragment that builds up in Alzheimer's disease. Computational analysis of large human sequence databases has predicted more than 400 distinct missense variants that could damage the enzyme, and the argument is that carrying one damaging copy may raise Alzheimer's risk.

Treat that as a hypothesis with a decent mechanism behind it, not a result you can act on. It comes from modeling population sequence data, not from following carriers and non-carriers over years to see who develops dementia.

Muscle, Strength, and the Fitness-Gene Claims

This gene shows up in many consumer endurance-versus-power DNA reports, and the evidence does not support how it is sold. In 225 older men and women put through a supervised strength training program, genotype was associated with how much muscle they started with, and not with how much muscle or strength they gained. The training worked regardless.

One finding survives. Among men with age-related muscle loss, the DD group tested weaker than the rest. That describes a starting point. Nothing in it tells you to train differently, and in the same trial genotype did not predict who responded to ACE inhibitor treatment.

When a Genetic Result Can Mislead

• Panel coverage: a negative result only rules out the variants and regions the assay was built to detect. Many reports do not include the I/D call.
• Uncertain findings: sequencing routinely turns up variants of uncertain significance, changes nobody has yet classified as harmful or harmless. One of those is not a diagnosis and should not drive any decision.
• Ancestry: allele frequencies and disease associations differ sharply between populations. The deletion allele tracked strongly with high blood pressure in a Ghanaian study and showed no association in a Jordanian one.
• Old I/D results: the original gel-based method can misread ID heterozygotes as DD unless an insertion-specific primer is used. If you are holding a DD result from years ago, it may simply be wrong.
• Wrong source: tumor sequencing, a consumer raw-data file, and a clinical germline test are not interchangeable. Confirm any result that would change a medical or family decision.
• Sample or reporting problems: germline results should match across blood, saliva, and buccal cells. Low-quality samples, contamination, or a tumor-only report can make the call unreliable.

A Result You Only Need Once

Your genotype was set at conception and will not change, so there is no trend to follow and no reason to repeat this test. The value lives in what it makes you do over the next several decades, not in the result itself.

What does need repeating is the phenotype side, the things your body is doing now. If you carry the deletion allele and you have diabetes, high blood pressure, or kidney failure in the family, check eGFR and a urine albumin-to-creatinine ratio as a baseline. eGFR estimates kidney filtration. Repeat in three to six months if anything is off or you are changing treatment, and at least yearly after that. If a blood enzyme level is being used to follow sarcoidosis, that gets rechecked on your specialist's schedule, now read against your genotype.

What to Do With an Unexpected Result

Two kinds of result are worth acting on. Most are not.

• A damaging variant in both copies: this is a real diagnosis. Confirm it by a second method, get a nephrologist involved, and have biological relatives tested, since each full sibling has a one-in-four chance of carrying the same pair.
• One damaged copy: you are a carrier. It matters most for family planning and for your children's risk if your partner also carries one. A genetic counselor earns the appointment here.
• A variant of uncertain significance: do nothing clinical. Ask the lab to notify you if it gets reclassified, which happens as databases grow.
• A common genotype such as DD, ID, or II: no workup follows from the genotype alone. Use it to decide how closely you watch kidney function and blood pressure, and, if sarcoidosis is being followed, to read your enzyme level correctly.

The one conversation this test earns is with biological family. Unlike a cholesterol number, a genotype is shared property: your parents, siblings, and children each carry a predictable slice of the same DNA. If sequencing found something real, they deserve to know it exists.